SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Appelbaum FR,Gundacker H,Head DR, et al. Age and acute myeloid leukemia. Blood. 2006; 107: 34813485.
  • 2
    Roboz GJ. Treatment of acute myeloid leukemia in older patients. Expert Rev Anticancer Ther. 2007; 7: 285295.
  • 3
    Menzin J,Lang K,Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002; 162: 15971603.
  • 4
    Degos L,Castaigne S,Tilly H, et al. Treatment of leukemia with low-dose ara-C: a study of 160 cases. Semin Oncol. 1985; 12: 196199.
  • 5
    Cheson BD,Jasperse DM,Simon R, et al. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol. 1986; 4: 18571864.
  • 6
    Burnett AK,Milligan D,Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007; 109: 11141124.
  • 7
    Schiller GJ,Slack J,Hainsworth JD, et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol. 2006; 24: 24562464.
  • 8
    Vey N,Bosly A,Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol. 2006; 24: 24652471.
  • 9
    Parmar S,Rundhaugen LM,Boehlke L, et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res. 2004; 28: 909919.
  • 10
    Douer D,Watkins K,Louie R, et al. Treatment of non-APL acute myelogenous leukemia with intravenous arsenic trioxide plus ascorbic acid [ASH Annual Meeting Abstracts]. Blood. 2006; 108. Abstract 1959.
  • 11
    Rojewski MT,Baldus C,Knauf W, et al. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. Br J Haematol. 2002; 116: 555563.
  • 12
    Rojewski MT,Korper S,Schrezenmeier H. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. Leuk Lymphoma. 2004; 45: 23872401.
  • 13
    Roboz GJ,Dias S,Lam G, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood. 2000; 96: 15251530.
  • 14
    Miller WHJr,Schipper HM,Lee JS, et al. Mechanisms of action of arsenic trioxide. Cancer Res. 2002; 62: 38933903.
  • 15
    Douer D,Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol. 2005; 23: 23962410.
  • 16
    Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 17
    Mayer RJ,Davis RB,Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994; 331: 896903.
  • 18
    Stone RM,Berg DT,George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995; 332: 16711677.
  • 19
    Rowe JM,Andersen JW,Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995; 86: 457462.
  • 20
    Godwin JE,Kopecky KJ,Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1998; 91: 36073615.
  • 21
    Lowenberg B,Suciu S,Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy–the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998; 16: 872881.
  • 22
    Goldstone AH,Burnett AK,Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001; 98: 13021311.
  • 23
    Anderson JE,Kopecky KJ,Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood. 2002; 100: 38693876.
  • 24
    Buchner T,Hiddemann W,Berdel WE, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and 1 course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. 2003; 21: 44964504.
  • 25
    Rowe JM,Neuberg D,Friedenberg W, et al. A phase 3 study of 3 induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004; 103: 479485.
  • 26
    Burnett AK,Mohite U. Treatment of older patients with acute myeloid leukemia–new agents. Semin Hematol. 2006; 43: 96106.